Leerink Partnrs Comments on United Therapeutics Co.’s FY2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of United Therapeutics in a research note issued on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of $25.91 for the year, down from their prior forecast of $25.95. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2024 earnings at $6.67 EPS and FY2025 earnings at $26.98 EPS.

A number of other brokerages have also issued reports on UTHR. HC Wainwright reissued a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $292.67.

United Therapeutics Stock Up 0.7 %

UTHR stock opened at $236.93 on Friday. The firm has a market cap of $11.15 billion, a PE ratio of 11.94 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The firm’s 50 day moving average price is $231.20 and its 200-day moving average price is $228.44. United Therapeutics has a one year low of $204.44 and a one year high of $261.54.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics’s revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.67 EPS.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total value of $1,290,060.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,869,150.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,166.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 126,190 shares of company stock valued at $29,672,157. Corporate insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Great West Life Assurance Co. Can raised its position in shares of United Therapeutics by 8.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company’s stock worth $5,244,000 after buying an additional 2,320 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of United Therapeutics by 229.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company’s stock worth $371,000 after buying an additional 1,437 shares in the last quarter. Prudential PLC bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $1,160,000. Zions Bancorporation N.A. bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $66,000. Finally, Covestor Ltd raised its holdings in shares of United Therapeutics by 187.5% in the 1st quarter. Covestor Ltd now owns 877 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 572 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.